EGFR and non-small cell lung carcinoma: EGFR mutation‐positive advanced NSCLC and EGFR tyrosine kinase inhibitors (TKIs) treatment is associated with better survival outcomes and fewer side effects than treatment with standard first‐line platinum‐based chemotherapy.4, 5